Health Care & Life Sciences » Biotechnology | Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
10,531.00
9,625.00
12,070.00
35,504.00
22,546.00
40,130
Cost of Goods Sold (COGS) incl. D&A
-
-
-
1,924.00
2,525.00
20,583
Gross Income
-
-
-
33,580.00
20,021.00
19,547
SG&A Expense
93,271.00
145,649.00
237,934.00
303,165.00
292,700.00
364,867
EBIT
84,099.00
137,566.00
227,175.00
-
272,679.00
345,320
Unusual Expense
206.00
114.00
-
-
-
-
Non Operating Income/Expense
441.00
155.00
-
1,533.00
1,338.00
13,516
Interest Expense
-
-
-
61.00
11,603.00
18,740
Pretax Income
83,352.00
137,125.00
226,870.00
268,113.00
285,620.00
350,544
Income Tax
-
-
365.00
-
-
-
Consolidated Net Income
83,352.00
137,125.00
226,505.00
268,113.00
285,620.00
350,544
Net Income
83,352.00
137,125.00
226,505.00
269,043.00
286,090.00
350,223
Net Income After Extraordinaries
83,352.00
137,125.00
226,505.00
269,043.00
286,090.00
350,223
Net Income Available to Common
83,352.00
137,125.00
226,505.00
269,043.00
286,090.00
350,223
EPS (Basic)
3.65
3.19
4.36
4.76
4.81
5.30
Basic Shares Outstanding
22,842.40
42,977.50
51,981.50
56,480.60
59,508.20
66,017.30
EPS (Diluted)
3.65
3.19
4.36
4.76
4.81
5.31
Diluted Shares Outstanding
22,842.40
42,977.50
51,981.50
56,480.60
59,508.20
66,017.30
EBITDA
82,740.00
136,024.00
225,864.00
267,661.00
270,269.00
342,218
Non-Operating Interest Income
100.00
400.00
305.00
-
-
-
Minority Interest Expense
-
-
-
930.00
470.00
321

About Portola Pharmaceuticals

View Profile
Address
270 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.portola.com
Updated 07/08/2019
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.